Vaccine maker Indian Immunologicals has increased its footprint in New Zealand with opening of a sterile filtered serum manufacturing facility of its subsidiary Pristine Biologicals NZ.
Setting up of the new facility, in Dargaville, comes in the backdrop of a growing demand for bovine serum from New Zealand for use in biologics manufacture. It has become important to augment capacities and bring in more value-added products, IIL said in a release on Monday.
Many vaccine manufacturers in India had expressed concerned at difficulty in obtaining quality serum and approached IIL for assistance. A senior official to the Centre’s Department of Animal Husbandry, Dairying and Fisheries had urged IIL to ramp up serum production capacity at Pristine and make available the product to Indian firms on a priority basis.
